Literature DB >> 29102768

Brain-derived neurotrophic factor (BDNF) and neurotrophin 3 (NT3) levels in post-mortem brain tissue from patients with depression compared to healthy individuals - a proof of concept study.

A Sheldrick1, S Camara2, M Ilieva3, P Riederer4, T M Michel5.   

Abstract

The neurotrophic factors (NTF) hypothesis of depression was postulated nearly a decade ago and is nowadays widely acknowledged. Previous reports suggest that cerebral concentrations of NTF may be reduced in suicide victims who received minimal or no antidepressant pharmacotherapy. Recent evidence suggests that antidepressant treatment may improve or normalise cerebral concentrations of neurotrophic factors. Therefore, we examined the concentration of brain-derived neurotrophic factor (BDNF) and neurotrophin 3 (NT3) in different brain regions (cortex, cingulate gyrus, thalamus, hippocampus, putamen and nucleus caudatus) of 21 individuals - 7 patients of which 4 patients with major depressive disorder (MDD) and overall age 86.8±5 years who received antidepressant pharmacotherapy (selective serotonin re-uptake inhibitors [SSRI]; tricyclic antidepressants [TCA]), 3 patients with MDD without antidepressant treatment and overall age 84.3±5 years versus 14 unaffected subjects at age 70.3±13.8. We detected significant elevation of BDNF (parietal cortex) and NT3 (parietal, temporal and occipital cortex, cingulate gyrus, thalamus, putamen and nucleus caudatus regions) in MDD patients who received antidepressant medication compared to MDD untreated patients and controls. Moreover, we detected a significant decrease of NT3 levels in the parietal cortex of patients suffering from MDD non-treated patients without treatment compared to healthy individuals. Although the limited statistical power due to the small sample size in this proof of concept study corroborates data from previous studies, which show that treatment with antidepressants mediates alterations in neuroplasticity via the action of NTF. However, more research using post-mortem brain tissue with larger samples needs to be carried out as well as longitudinal studies to further verify these results.
Copyright © 2017 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Affective disorders; Antidepressants; Depression; Molecular biology; Psychiatry; Psychopharmacology

Mesh:

Substances:

Year:  2017        PMID: 29102768     DOI: 10.1016/j.eurpsy.2017.06.009

Source DB:  PubMed          Journal:  Eur Psychiatry        ISSN: 0924-9338            Impact factor:   5.361


  12 in total

1.  The Role of Epigenetic Dysregulation in Suicidal Behaviors.

Authors:  Laura M Fiori; Gustavo Turecki
Journal:  Curr Top Behav Neurosci       Date:  2020

2.  Disorders of Hippocampus Facilitated by Hypertension in Purine Metabolism Deficiency is Repressed by Naringin, a Bi-flavonoid in a Rat Model via NOS/cAMP/PKA and DARPP-32, BDNF/TrkB Pathways.

Authors:  J K Akintunde; O S Abinu; K F Taiwo; R A Sodiq; A D Folayan; A D Ate
Journal:  Neurotox Res       Date:  2022-09-13       Impact factor: 3.978

3.  Association of peripheral manifestation of brain-derived neurotrophic factor with depression: A meta-analysis.

Authors:  Sagun Tiwari; Lili Qi; John Wong; Zhenxiang Han
Journal:  Brain Behav       Date:  2022-05-05       Impact factor: 3.405

4.  Inhibition of Phosphodiesterase 4 by FCPR03 Alleviates Chronic Unpredictable Mild Stress-Induced Depressive-Like Behaviors and Prevents Dendritic Spine Loss in Mice Hippocampi.

Authors:  Hui Yu; Jiahong Zhong; Bo Niu; Qiuping Zhong; Jiao Xiao; Jinfeng Xie; Manna Lin; Zhongzhen Zhou; Jiangping Xu; Haitao Wang
Journal:  Int J Neuropsychopharmacol       Date:  2019-02-01       Impact factor: 5.176

5.  Cerebrospinal fluid neuroplasticity-associated protein levels in patients with psychiatric disorders: a multiplex immunoassay study.

Authors:  Shinsuke Hidese; Kotaro Hattori; Daimei Sasayama; Takuya Tsumagari; Tomoko Miyakawa; Ryo Matsumura; Yuuki Yokota; Ikki Ishida; Junko Matsuo; Sumiko Yoshida; Miho Ota; Hiroshi Kunugi
Journal:  Transl Psychiatry       Date:  2020-05-21       Impact factor: 6.222

Review 6.  Changes in neuroplasticity following early-life social adversities: the possible role of brain-derived neurotrophic factor.

Authors:  Christina Miskolczi; József Halász; Éva Mikics
Journal:  Pediatr Res       Date:  2018-10-15       Impact factor: 3.756

7.  Altered levels of interleukins and neurotrophic growth factors in mood disorders and suicidality: an analysis from periphery to central nervous system.

Authors:  Bharathi S Gadad; Javier Vargas-Medrano; Enrique Ivan Ramos; Katherine Najera; Matthew Fagan; Angelica Forero; Peter M Thompson
Journal:  Transl Psychiatry       Date:  2021-06-02       Impact factor: 6.222

8.  Inhibition of Phosphodiesterase 4 by FCPR03 Alleviates Lipopolysaccharide-Induced Depressive-Like Behaviors in Mice: Involvement of p38 and JNK Signaling Pathways.

Authors:  Hui Yu; Zhengqiang Zou; Xiaolin Zhang; Wanli Peng; Chen Chen; Yicheng Ye; Jiangping Xu; Haitao Wang
Journal:  Int J Mol Sci       Date:  2018-02-08       Impact factor: 5.923

9.  Diterpene Ginkgolides Exert an Antidepressant Effect Through the NT3-TrkA and Ras-MAPK Pathways.

Authors:  Ting Wang; Shunjie Bai; Wei Wang; Zhi Chen; Jianjun Chen; Zihong Liang; Xunzhong Qi; Hailan Shen; Peng Xie
Journal:  Drug Des Devel Ther       Date:  2020-03-31       Impact factor: 4.319

10.  Sulforaphane activates anti-inflammatory microglia, modulating stress resilience associated with BDNF transcription.

Authors:  Rui Tang; Qian-Qian Cao; Sheng-Wei Hu; Lu-Juan He; Peng-Fei Du; Gang Chen; Rao Fu; Fei Xiao; Yi-Rong Sun; Ji-Chun Zhang; Qi Qi
Journal:  Acta Pharmacol Sin       Date:  2021-07-16       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.